查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
组织诊断市场 - 2023-2028 年预测
市场调查报告书
商品编码
1295392

组织诊断市场 - 2023-2028 年预测

Tissue Diagnostics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021 年组织诊断市场价值 14.68 亿美元，预计在预测期内復合年增长率为 7.81%，到 2028 年达到 24.84 亿美元。

组织诊断市场是指涉及用于检查组织样本以诊断疾病和评估各种医疗状况的诊断测试和工具的开发、生产和商业化的行业。 该市场包括仪器、耗材、配件、免疫组织化学 (IHC)、原位杂交 (ISH)、数字病理学和特种染色技术等多种产品。 组织诊断在癌症诊断、传染病诊断、自身免疫性疾病诊断、心血管疾病诊断等领域发挥着重要作用。

慢性病患病率和患病率增加

癌症、心血管疾病和神经系统疾病等慢性疾病的患病率不断上升，将组织诊断的需求推向前所未有的高度。 世界卫生组织 (WHO) 报告称，慢性病占每年死亡人数的 74%，并夺去了大约 4100 万人的生命。 组织诊断包括各种组织病理学技术和分子测定，对于促进准确的疾病诊断和个性化治疗策略至关重要。 这些慢性疾病的复杂性需要全面了解其潜在的组织异常和分子改变，这可以通过组织诊断来有效实现。

人口老龄化

此外，到2021年，60岁及以上的人口还在增加。 由于这个年龄段容易患癌症，人口增长支撑了对组织诊断服务不断增长的需求。 医疗保健提供者和诊断公司必须扩大资源，以满足对准确的癌症诊断和治疗决策日益增长的需求。 组织诊断技术的进步可以在解决这些人群的癌症负担和改善患者预后方面发挥重要作用。

政府举措：

世界各国政府越来越认识到组织诊断技术对医疗保健和疾病管理产生重大影响的潜力。 这些技术为疾病诊断、个性化治疗计划和监测患者对治疗的反应提供了宝贵的见解。 通过支持组织诊断的引入和发展，政府旨在提高医疗保健效果并改善患者护理。

组织诊断市场的主要公司

组织诊断市场的主要参与者包括 Abbott Laboratories、Agilent Technologies、BD（Becton、Dickinson 和 Company）、BioGenex 和 Cardinal Health。 这些公司大力投资研发，开发新技术和解决方案，以满足不断增长的需求。 例如，2021年，Roche子公司Roche诊断公司推出了“Ventana HER2 Dual ISH DNA Probe Cocktail”。 该产品用于检测乳腺癌和胃癌组织样本中人表皮生长因子受体2（HER2）基因扩增情况。 它为临床医生提供了宝贵的信息，以确定适当的治疗方式，包括 HER2 抑製剂等靶向治疗。

诊断创新显着增加

过去几年，随着领先公司推出先进产品，免疫组织化学 (IHC) 市场的增长见证了诊断创新的显着增长。 例如，Roche的 DISCOVERY ULTRA 系统具有 30 个独立的滑动抽屉，提高了同时运行手动和全自动实验的能力，而不会遇到同步问题。 使用该系统可以完全自动化进行各种 IHC 和 ISH 实验，包括 FISH、蛋白质 IHC/ISH 和多重测定。 同样，Creative Diagnostics 于 2021 年 12 月发布了一系列全面的免疫组织化学病理学抗体。

医院使用高比例的组织诊断解决方案。

基于医院组织的诊断测试正在取代传统的测试技术。 这是因为组织学诊断检查比传统技术花费的时间更少。 慢性病患病率的上升也增加了医院对组织诊断的需求。 例如，根据美国癌症协会 2022 年 1 月发布的《2022 年癌症事实和数据》，预计 2022 年将确诊 190 万个新癌症病例。 癌症患病率的上升和其他慢性疾病的沉重负担增加了对准确诊断和治疗的需求。

本地见解：

按地区划分，组织诊断市场分为北美、南美、欧洲、中东和非洲以及亚太地区。 北美地区，尤其是美国，拥有完善的医疗基础设施和先进的诊断技术，使其成为组织诊断的强大市场。 欧洲也是组织诊断的重要市场，德国、法国和英国等国家在市场规模和诊断技术进步方面处于领先地位。 该地区重视早期诊断、完善的医疗保健系统以及不断增强的癌症筛查和预防意识。

美国处于组织诊断市场的前沿，是北美最大、最具活力的市场。 凭藉其先进的医疗基础设施、广泛的研发能力和高癌症发病率，该国为组织诊断的增长和创新提供了肥沃的土壤。 美国拥有许多行业领先企业，推动了竞争和技术进步。 随着医疗保健提供者努力寻求准确的诊断和个性化的治疗方法，对精准医疗和个性化医疗保健的重视进一步推动了组织诊断的采用。 美国专注于研究、合作和尖端技术，在塑造组织诊断的未来、改善患者治疗结果和推动医疗诊断领域发展方面发挥着关键作用。

市场趋势：

  • 2021年5月，全球分子诊断领域领导者QIAGEN推出了therascreen(R) KRAS RGQ PCR试剂盒，作为首个获得美国FDA批准的NSCLC肿瘤组织伴随诊断试剂盒，对市场影响做出了重大贡献。 这一创新解决方案可识别 NSCLC 中普遍存在的 KRAS G12C 突变，并为指导治疗决策提供重要见解。
  • 例如，Oncotype DX 是领先的个性化医疗诊断技术之一，它分析 21 个基因来识别无需化疗即可治疗的乳腺癌患者。 2021年，个性化医疗将赢得近三分之一的FDA新药批准，并在过去七年中占FDA批准的25%以上。 AstraZeneca等大型製药公司已证实，精准医疗约占其研发收入的 90%。

内容

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第 2 章研究方法

  • 调查设计
  • 调查数据
  • 验证

第 3 章执行摘要

  • 主要发现

第 4 章市场动态

  • 市场驱动因素
  • 市场製约因素
  • 波特五力分析
  • 行业价值链分析

第 5 章组织诊断市场：按产品

  • 简介
  • 消耗品
    • 抗体
    • 套件
    • 探测
    • 试剂
  • 设备
    • 幻灯片扫描仪
    • 载玻片染色系统
    • 组织微阵列
    • 组织处理系统
    • 其他

第 6 章：组织诊断市场：按技术划分

  • 简介
  • 数字病理学和工作流程管理
  • 免疫组织化学 (IHC)
  • 原位杂交 (ISH)
  • 初级特种染色

第 7 章：组织诊断市场：按应用划分

  • 简介
  • 乳腺癌
  • 宫颈癌
  • 结直肠癌
  • 胃癌
  • 肺癌
  • 其他

第 8 章：组织诊断市场：按最终用户划分

  • 简介
  • 合同研究组织 (CRO)
  • 医院
  • 诊断中心
  • 其他

第 9 章：组织诊断市场：按地区

  • 简介
  • 北美
    • 按产品
    • 按技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按产品
    • 按技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按产品
    • 按技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东和非洲
    • 按产品
    • 按技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按产品
    • 按技术
    • 按用途
    • 按最终用户
    • 按国家/地区

第10章竞争格局与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 合併、收购、协议与合作
  • 供应商竞争力矩阵

第 11 章公司简介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BD（Becton, Dickinson, and Company）
  • BioGenex
  • Cardinal Health
  • Danaher
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Medtronic
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: KSI061610034

The tissue diagnostics market was valued at US$1.468 billion in 2021 and is expected to grow at a CAGR of 7.81% over the forecast period to reach a market size of US$2.484 billion by 2028.

The tissue diagnostics market refers to the industry that involves the development, production, and commercialization of diagnostic tests and tools used to examine tissue samples to diagnose diseases or assess various medical conditions. This market includes multiple products such as instruments, consumables, accessories, and technologies like immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining techniques. Tissue diagnostics play a crucial role in areas such as cancer diagnosis, infectious disease diagnosis, autoimmune disease diagnosis, cardiovascular disease diagnosis, and more.

Increasing prevalence and incidence of chronic diseases.

The rising prevalence of chronic diseases, including cancer, cardiovascular diseases, and neurological disorders, has propelled the demand for tissue diagnostics to unprecedented heights. Globally, chronic diseases are responsible for 74% of all deaths annually, resulting in the loss of approximately 41 million lives, as the World Health Organization (WHO) reported. Tissue diagnostics, comprising a range of histopathological techniques and molecular assays, are pivotal in facilitating accurate disease diagnosis and tailored treatment strategies. The intricate nature of these chronic conditions necessitates a comprehensive understanding of the underlying tissue abnormalities and molecular alterations, which can be effectively achieved through tissue diagnostics.

The growing geriatric population.

Additionally, the growing population of individuals aged 60 years and older has increased in 2021. As this age group is more susceptible to developing cancer, the rising population size underscores the increased demand for tissue diagnostics services. Healthcare providers and diagnostic companies must adapt and expand their resources to meet the growing need for accurate cancer diagnosis and treatment decision-making. Advancements in tissue diagnostic technologies can play a crucial role in addressing the burden of cancer in these demographics and improving patient outcomes.

Favorable government initiatives:

Governments worldwide are increasingly recognizing the potential of tissue diagnostics technologies, including their significant impact on healthcare and disease management. These technologies offer valuable insights into disease diagnosis, personalized treatment planning, and monitoring patient response to therapy. Governments aim to enhance healthcare outcomes and improve patient care by supporting the adoption and advancement of tissue diagnostics.

Key players in the tissue diagnostics market

Key players in the tissue diagnostics market include Abbott Laboratories, Agilent Technologies, BD (Becton, Dickinson, and Company), BioGenex, and Cardinal Health. These companies invest heavily in research and development to develop new technologies and solutions to meet the growing demand. For instance, in 2021, "Ventana HER2 Dual ISH DNA Probe Cocktail" was launched by Roche Diagnostics, a subsidiary of F. Hoffmann-La Roche Ltd. This product is used to detect human epidermal growth factor receptor 2 (HER2) gene amplification in breast and gastric cancer tissue samples. It provides clinicians with valuable information for determining the appropriate treatment approach, such as targeted therapies like HER2 inhibitors.

Significant increase in diagnostic innovation

The previous few years have seen a significant increase in diagnostic innovation, due to which major corporations have introduced advanced products for the growing immunohistochemistry (IHC) market. For instance, the DISCOVERY ULTRA system by Roche enhances the capacity to execute manual and completely automated experiments concurrently without experiencing synchronization issues because of its 30 independent slide drawers. A wide variety of IHC and ISH experiments, comprising FISH, protein IHC/ISH, and multiplex assays, among others, can be fully automated using the system. Similarly, Creative Diagnostics released a comprehensive array of immunohistochemistry pathology antibodies in December 2021.

Hospitals use tissue diagnostic solutions at high rates.

Tissue-based diagnostic testing by hospitals is replacing more conventional testing techniques. This is because tissue diagnostic tests take less time than traditional techniques. the rising prevalence of chronic diseases also increases the demand for tissue diagnostics in hospitals. For instance, an estimated 1.9 million new cancer cases were identified in 2022, according to Cancer Facts and Figures 2022, released in January 2022 by the American Cancer Society. The rising incidence of cancer and the heavy load of other chronic diseases enhance the need for precise diagnosis and treatment.

Geographical Insights:

Based on geography, the tissue diagnostics market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The North American region, particularly the United States, has a well-established healthcare infrastructure and advanced diagnostic technologies, making it a prominent market for tissue diagnostics. Europe is another significant market for tissue diagnostics, with countries like Germany, France, and the United Kingdom leading in terms of market size and advancements in diagnostic technologies. The region benefits from a strong focus on early disease diagnosis, well-established healthcare systems, and increasing cancer screening and prevention awareness.

The United States is at the forefront of the tissue diagnostics market, representing North America's largest and most dynamic market. With its advanced healthcare infrastructure, extensive research and development capabilities, and high prevalence of cancer, the country offers a fertile ground for the growth and innovation of tissue diagnostics. The United States houses numerous leading players in the industry, driving competition and technological advancements. The emphasis on precision medicine and personalized healthcare further propels the adoption of tissue diagnostics as healthcare providers strive for accurate diagnoses and tailored treatment approaches. With a strong focus on research, collaborations, and cutting-edge technologies, the United States plays a pivotal role in shaping the future of tissue diagnostics, improving patient outcomes, and advancing the field of healthcare diagnostics.

Market Developments:

  • In May 2021, QIAGEN, a global leader in molecular diagnostics, made a significant contribution to the market by launching their therascreen® KRAS RGQ PCR Kit as the first US FDA-approved tissue companion diagnostic for NSCLC tumors. This innovative solution identifies the KRAS G12C mutation, a prevalent mutation in NSCLC, and provides crucial insights for guiding treatment decisions.
  • One of the advanced diagnostics for personalized medicine, Oncotype DX, for instance, analyses 21 genes to identify breast cancer patients who can be treated without chemotherapy. In 2021, personalized medicines received almost a third of all FDA approvals for new drugs and over 25% of all FDA approvals over the previous seven years. Major pharmaceutical firms like AstraZeneca confirm precision therapies provide about 90% of their research and development income.

Market Segmentation:

By Product

  • Consumables
  • Antibodies
  • Kits
  • Probes
  • Reagents
  • Instruments
  • Slide Scanners
  • Slide Staining Systems
  • Tissue Microarrays
  • Tissue Processing Systems
  • Others

By Technology

  • Digital Pathology and Workflow Management
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Primary Special Staining

By Application

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Lung cancer
  • Others

By End-Users

  • Contract Research Organizations (CROs)
  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Data
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. TISSUE DIAGNOSTICS MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Consumables
    • 5.2.1. Antibodies
    • 5.2.2. Kits
    • 5.2.3. Probes
    • 5.2.4. Reagents
  • 5.3. Instruments
    • 5.3.1. Slide Scanners
    • 5.3.2. Slide Staining Systems
    • 5.3.3. Tissue Microarrays
    • 5.3.4. Tissue Processing Systems
    • 5.3.5. Others

6. TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Digital Pathology and Workflow Management
  • 6.3. Immunohistochemistry (IHC)
  • 6.4. In Situ Hybridization (ISH)
  • 6.5. Primary Special Staining

7. TISSUE DIAGNOSTICS MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Breast cancer
  • 7.3. Cervical cancer
  • 7.4. Colorectal cancer
  • 7.5. Gastric cancer
  • 7.6. Lung Cancer
  • 7.7. Others

8. TISSUE DIAGNOSTICS MARKET, BY END-USER

  • 8.1. Introduction
  • 8.2. Contract Research Organizations (CROs)
  • 8.3. Hospitals
  • 8.4. Diagnostic Centers
  • 8.5. Others

9. TISSUE DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
    • 9.2.5.1. United States
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Technology
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Technology
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
    • 9.4.5.1. Germany
    • 9.4.5.2. France
    • 9.4.5.3. United Kingdom
    • 9.4.5.4. Italy
    • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Technology
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
    • 9.5.5.1. UAE
    • 9.5.5.2. Saudi Arabia
    • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Technology
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
    • 9.6.5.1. Japan
    • 9.6.5.2. China
    • 9.6.5.3. South Korea
    • 9.6.5.4. India
    • 9.6.5.5. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Abbott Laboratories
  • 11.2. Agilent Technologies, Inc.
  • 11.3. BD (Becton, Dickinson, and Company)
  • 11.4. BioGenex
  • 11.5. Cardinal Health
  • 11.6. Danaher
  • 11.7. Exact Sciences Corporation
  • 11.8. F. Hoffmann-La Roche Ltd
  • 11.9. Medtronic
  • 11.10. Merck KGaA
  • 11.11. Thermo Fisher Scientific Inc.